Teijin, Takeda Accuse Lupin Of Infringing Uloric Patent

Law360, Washington (February 12, 2014, 6:47 PM EST) -- Japanese drugmakers Teijin Ltd. and Takeda Pharmaceuticals Co. Ltd. sued Indian rival Lupin Ltd. in Delaware federal court Wednesday, accusing it of infringing a Teijin-owned patent with its planned generic version of Takeda's gout treatment Uloric.

According to the plaintiffs, the 40- and 80-milligram tablets of generic febuxostat planned for release by Lupin's U.S.-based unit Lupin Pharmaceuticals Inc. infringe U.S. Patent Number 6,225,474, licensed by Teijin to Takeda subsidiary Takeda Pharmaceuticals U.S.A. Inc. for use in Uloric.

“Plaintiffs will be irreparably harmed by Lupin's infringing activities,...
To view the full article, register now.